1. Serum matrix metalloproteinases in adult CF patients: Relation to pulmonary exacerbation 
Martin Roderfeld, Timo Rath, Richard Schulz, Werner Seeger, Annette Tschuschner, Jürgen Graf, Elke Roeb 
Journal of Cystic Fibrosis 
Volume 8, Issue 5, Pages (September 2009)
DOI: /j.jcf
Copyright © 2009 European Cystic Fibrosis Society. Terms and Conditions

2. Fig. 1
a. Serum MMP-1 (A), MMP-2 (B), MMP-3 (C), MMP-7 (D), MMP-8 (E) protein concentrations in healthy control subjects (n=40), CF patients without pulmonary exacerbation (CF-no PEx, n=38), and CF patients suffering from pulmonary exacerbation (CF-PEx, n=16). Protein assay was performed by multi analyte ELISA. Significant differences are pointed out (⁎P<0.05, ⁎⁎P<0.01). Compared with healthy subjects, MMP-8 showed enhanced protein levels in CF patients without PEx (2.2-fold, P<0.001) and further progression in those with PEx (3.8-fold, P<0.001). Moreover, MMP-8 protein was significantly expressed higher in CF patients with PEx than in those without PEx (1.7-fold, P<0.001). MMP-1 was elevated in CF patients with PEx compared to those without PEx (2.2-fold, P=0.014) and healthy subjects (2.5-fold, P=0.021). Compared to healthy controls, MMP-2 showed progressive decreased expression from CF patients without PEx (−1.4-fold, P<0.001) to those with PEx (−1.7-fold, P<0.001). Patients with PEx revealed significantly reduced MMP-2 expression compared to those without PEx (−1.2-fold, P=0.015). Data are presented in box-and-whisker-plots. Values deviating from the box by 1.5- to 3-fold interquartile range were defined as outliers (o). Extreme values (Δ) with a distance of more than 3 box-lengths were not considered for statistical analysis. b. Serum protein concentrations of total (A) and active (B) MMP-9, TIMP-1 (C), and the MMP-9/TIMP-1-ratio (D) in healthy control subjects (n=40), CF patients without pulmonary exacerbation (CF-no PEx, n=38), and CF patients suffering from pulmonary exacerbation (CF-PEx, n=16). Protein assay was performed by multi analyte ELISA. Significant differences are pointed out (⁎P<0.05, ⁎⁎P<0.01). Compared with healthy subjects, total and active MMP-9 showed enhanced protein levels in CF patients without PEx (total MMP-9: 1.4-fold, P<0.001; active MMP-9: 7.9-fold, P<0.001) and further progression in those with PEx (total MMP-9: 2.3-fold, P<0.001, MMP-9 activity: 10.3-fold, P<0.001). TIMP-1 was enhanced in CF patients with PEx compared to those without PEx (1.1-fold, P=0.013) and healthy controls (1.1-fold, P=0.007). The MMP-9/TIMP-1-ratio was significantly increased in both, patients with (2-fold, P=0.001) and without (1.5-fold, P=0.001) pulmonary exacerbation compared to healthy controls. Data are presented in box-and-whisker-plots. Values deviating from the box by 1.5- to 3-fold interquartile range were defined as outliers (o). Extreme values (Δ) with a distance of more than 3 box-lengths were not considered for statistical analysis.
Journal of Cystic Fibrosis 2009 8, DOI: ( /j.jcf )
Copyright © 2009 European Cystic Fibrosis Society. Terms and Conditions

3. Fig. 2
Serum levels of MMP-1 (A), MMP-8 (B), total (C) and active MMP-9 (D), TIMP-1 (E) protein and the MMP-9/TIMP-1 ratio (F) in CF patients with pulmonary exacerbation before and after initiation of antimicrobial therapy. Antibiotic treatment led to a significant decline of serum MMP-8 (P=0.028), active MMP-9 (P=0.028) and MMP-1 protein concentration (P=0.018). Reduction of total MMP-9, TIMP-1 and of the MMP-9/TIMP-1 ratio did not reach the level of statistical significance (MMP-9: P=0.176, TIMP-1: P=0.063, MMP-9/TIMP-1 ratio: P=0.237). Data are presented in box-and-whisker-plots. Values deviating from the box by 1.5- to 3-fold interquartile range were defined as outliers (o). Extreme values (Δ) with a distance of more than 3 box-lengths were not considered for statistical analysis.
Journal of Cystic Fibrosis 2009 8, DOI: ( /j.jcf )
Copyright © 2009 European Cystic Fibrosis Society. Terms and Conditions